Evidence map›Paper›PMID 41597900›Full record

ReviewMicromachines2026

Plasmonics Meets Metasurfaces: A Vision for Next Generation Planar Optical Systems.

Muhammad A Butt

Abstract readReview
In one paragraph

Review in Micromachines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Muhammad A ButtInstitute of Microelectronics and Optoelectronics, Warsaw University of Technology, Koszykowa 75, 00-662 Warsaw, Poland.ORCID 0000-0003-0829-4886

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasmonics and metasurfaces (MSs) have emerged as two of the most influential platforms for manipulating light at the nanoscale, each offering complementary strengths that challenge the limits of conventional optical design. Plasmonics enables extreme subwavelength field confinement, ultrafast light-matter interaction, and strong optical nonlinearities, while MSs provide versatile and compact control over phase, amplitude, polarization, and dispersion through planar, nanostructured interfaces. Recent advances in materials, nanofabrication, and device engineering are increasingly enabling these technologies to be combined within unified planar and hybrid optical platforms. This review surveys the physical principles, material strategies, and device architectures that underpin plasmonic, MS, and hybrid plasmonic-dielectric systems, with an emphasis on interface-mediated optical functionality rather than long-range guided-wave propagation. Key developments in modulators, detectors, nanolasers, metalenses, beam steering devices, and programmable optical surfaces are discussed, highlighting how hybrid designs can leverage strong field localization alongside low-loss wavefront control. System-level challenges including optical loss, thermal management, dispersion engineering, and large-area fabrication are critically examined. Looking forward, plasmonic and MS technologies are poised to define a new generation of flat, multifunctional, and programmable optical systems. Applications spanning imaging, sensing, communications, augmented and virtual reality, and optical information processing illustrate the transformative potential of these platforms. By consolidating recent progress and outlining future directions, this review provides a coherent perspective on how plasmonics and MSs are reshaping the design space of next-generation planar optical hardware.

Indexed as

hybrid plasmonic systemmetasurfacesmodulatorsnanolaserplasmonics

Identifiers

PMID41597900
PMCPMC12844466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.